Generics Act of 1988

Also known as: Republic Act No. 6675 · RA 6675 · Generics Law of 1988 · The Generics Act

Definition

The Generics Act of 1988 is the short title of Republic Act No. 6675, officially “An Act to Promote, Require and Ensure the Production of an Adequate Supply, Distribution, Use and Acceptance of Drugs and Medicines Identified by their Generic Names, as well as to Ensure the Provision of Information to the General Public on the Proper Use and Cautions in the Use of Drugs and Medicines.” The bill was passed by the Senate on August 25, 1988 and by the House of Representatives on August 31, 1988, and was signed by President Corazon C. Aquino on September 13, 1988. The Act was the first legislation to operationalize the Philippine National Drug Policy advanced by the Department of Health (DOH) under Secretary Alfredo Bengzon, and it committed the government to making quality essential drugs available at the lowest possible cost, including free distribution to indigent patients where feasible. (LawPhil — RA 6675, Supreme Court E-Library — RA 6675)

The law’s core mechanism is mandatory generic-name identification. Every drug manufactured, imported, or sold in the Philippines must be labeled with its generic (international nonproprietary) name, prominently and legibly printed; physicians are required to indicate the generic name of the medicine prescribed, with the brand name permitted only as an addition; and drug outlets, including hospital pharmacies, are required to maintain a stock of drugs identified by their generic names. The DOH, through the Bureau of Food and Drugs (now the Food and Drug Administration), implements the Act and issues the administrative orders that carry penalties for violations. (LawPhil — RA 6675, Inquirer.net — More Filipinos turning to generic drugs)

Identities

Source Type	Identity
Wikipedia	N/A
Wikidata	N/A
DBpedia	N/A
ProductOntology	N/A
Wiktionary	N/A
Library of Congress Subject Headings (LCSH)	N/A
MeSH	N/A
NCBI Taxonomy	N/A
AGROVOC	N/A
Google Scholar	“Generics Act of 1988” RA 6675 Philippines generic prescribing
ConceptNet	N/A
OpenCyc	N/A

Also Known As

Republic Act No. 6675
RA 6675
Generics Law of 1988
The Generics Act

Examples and Analogies

Labeling analog: before the Act, a medicine might be known to consumers only by a marketed brand; the law requires the underlying generic name — for instance, paracetamol, the generic substance sold under many brands — to appear prominently on the label, so the brand becomes an optional identifier rather than the primary one.
Prescription analog: the prescription rule functions like a price-comparison mandate — by forcing the generic name onto every prescription, the law lets the pharmacist and the patient see cheaper equivalents of the same active substance, much as unit pricing lets shoppers compare goods by content rather than packaging.
Verified statutory data:
Short title: “Generics Act of 1988” (Section 1)
Approval: September 13, 1988, by President Corazon C. Aquino
Legislative history: consolidation of Senate Bill No. 453 and House Bill No. 10900
Key duties: generic labeling of all drugs; generic names in prescriptions; generic drug stocks in all outlets and hospital pharmacies
Implementing agency: Department of Health, through the Bureau of Food and Drugs
Constitutional challenge: upheld in Del Rosario v. Bengzon, G.R. No. 88265 (December 21, 1989)
Later reinforcement: Universally Accessible Cheaper and Quality Medicines Act of 2008 (RA 9502)

Usage Scenarios

1. Prescribing and Dispensing

In everyday clinical practice, a physician writes the generic name of each medicine on the prescription and may add a brand name; the pharmacist dispenses on that basis, which allows substitution toward more affordable generic equivalents and is intended to secure the patient’s choice between branded and unbranded versions of the same substance. (LawPhil — G.R. No. 88265)

2. Drug Outlet Operations

Drugstores, hospital pharmacies, and similar outlets must carry stocks of drugs identified by their generic names, giving the DOH a statutory lever for widening physical access to lower-priced medicines beyond the branded inventories of major retailers. (LawPhil — RA 6675)

3. Regulation and Enforcement

The DOH implements the Act through administrative orders, inspections, and sanctions — fines, imprisonment, and revocation of licenses to operate — against manufacturers, importers, distributors, and prescribers who violate the generic labeling and prescription requirements. (LawPhil — RA 6675, Supreme Court E-Library — RA 6675)

4. Public Information Campaigns

The law obliges the government to promote the acceptance of generic drugs and to provide the public information on their proper use and cautions, a mandate the DOH has pursued through advocacy, generic-medicine programs, and later tie-ins with cheaper-medicines initiatives. (Inquirer.net — More Filipinos turning to generic drugs)

5. Judicial Review

The Act’s validity was tested in Del Rosario v. Bengzon, where doctors and the Philippine Medical Association attacked the prescription and penalty provisions; the Supreme Court upheld the law as a valid exercise of police power in the service of public health. (LawPhil — G.R. No. 88265)

Strategies

Generic-name transparency as competition policy: by making the generic name the legal common denominator of labeling and prescribing, the Act sought to weaken brand loyalty as a pricing mechanism and open the market to generic competition. (LawPhil — RA 6675)
Physician-side and outlet-side mandates together: the law pairs the prescriber’s duty (generic names on prescriptions) with the retailer’s duty (generic stocks on shelves), so that demand-side and supply-side reforms reinforce each other.
Administrative implementation: rather than fixing prices directly, the Act vests the DOH with implementing rules and enforcement, allowing adjustments through administrative orders — the approach the Supreme Court validated against an undue-delegation challenge. (LawPhil — G.R. No. 88265)
Essential-drugs orientation: the statute ties its mandate to the adequacy of supply of safe, effective, and affordable drugs, aligning Philippine practice with the essential-medicines approach promoted internationally.
Legislative reinforcement over time: in 2008 Congress built on the Act through the Universally Accessible Cheaper and Quality Medicines Act, which further liberalized access to affordable medicines. (Inquirer.net — More Filipinos turning to generic drugs)

Security and Safety Measures

Drug-safety rationale: the Act’s stated aims include promoting drug safety by minimizing duplication in medications and ensuring that inexpensive, effective drugs reach consumers — framing generic naming as a safety, not merely a cost, measure. (Supreme Court E-Library — RA 6675)
Labeling safeguards: generic names must be printed prominently and legibly on labels, reducing confusion and accidental duplication of the same active substance across brands. (LawPhil — RA 6675)
Penalties: violations of the labeling, prescription, and stocking requirements carry fines, imprisonment, and revocation of professional or operating licenses. (LawPhil — RA 6675)
Quality assurance as implementation condition: studies of the Act emphasize that its acceptance depends on the government’s capacity to guarantee the quality of generic drugs and to disseminate information about them. (Dantes — The new Philippine generic drugs act)
Constitutional review: the penalty and delegation provisions survived scrutiny in Del Rosario v. Bengzon, which found them neither excessive nor an invalid delegation of legislative power. (LawPhil — G.R. No. 88265)

Historical Context

The Generics Act emerged from the health-policy reform agenda that followed the 1986 EDSA Revolution. The Aquino administration’s Philippine National Drug Policy, steered by Health Secretary Alfredo Bengzon, diagnosed a market dominated by multinational branded medicines at prices beyond the reach of most Filipinos; RA 6675, signed on September 13, 1988, became its first statutory instrument. The signing itself was controversial — contemporary reporting noted that the new law “stirs controversy” even as it was hailed by consumer and health advocates. (UCA News — President Aquino signs new generic drugs law, LawPhil — RA 6675)

Implementation was contested from the start. The Philippine Medical Association and individual physicians challenged the Act’s constitutionality, and in Del Rosario v. Bengzon (G.R. No. 88265, December 21, 1989) the Supreme Court upheld the law as a valid exercise of police power. A 1991 knowledge-attitude-practice survey by the physician R. B. Dantes found that a large majority of surveyed doctors were opposed to the Act, illustrating the compliance gap that would shadow the law for decades. Successive assessments — including the Philippine Institute for Development Studies’ policy note “How Effective Has the Generics Act Been?” — documented persistent consumer preference for brands and limited price impact, and in 2008 Congress responded with the Cheaper and Quality Medicines Act (RA 9502) to reinforce the generics agenda. (LawPhil — G.R. No. 88265, Dantes — The new Philippine generic drugs act, PIDS — How Effective Has the Generics Act Been?)

Challenges and Controversies

Physician Compliance Debates

The most durable controversy has been the prescribing requirement. Doctors argued that mandatory generic-name writing intruded on clinical practice and exposed them to penalties; the 1991 Dantes survey found roughly seventy percent of surveyed physicians opposed to the Act, and confusion persisted for years over whether brand names could be written at all. Defenders, including the Supreme Court, answered that the measure is a proportionate health regulation that actually secures the patient’s right to choose. (Dantes — The new Philippine generic drugs act, LawPhil — G.R. No. 88265)

Pharmaceutical Industry Pushback

Multinational drug companies and industry groups resisted the law at its passage and during implementation, contesting generic-only labeling norms and the administrative orders enforcing them; contemporary coverage of the September 1988 signing recorded the controversy that surrounded the measure. (UCA News — President Aquino signs new generic drugs law)

Effectiveness and Price Impact

Policy researchers have repeatedly questioned whether the Act achieved its affordability goals. PIDS analysis found medicine prices remained high and consumer behavior only partially shifted toward generics, prompting the 2008 Cheaper and Quality Medicines Act and continuing debates over enforcement, quality assurance, and information campaigns. (PIDS — How Effective Has the Generics Act Been?, Inquirer.net — More Filipinos turning to generic drugs)